TG Therapeutics (STU:NKB2) YoY EBITDA Growth : 78.42% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is TG Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. TG Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 78.42%.

TG Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €-0.05.

TG Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for TG Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics YoY EBITDA Growth Chart

TG Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

15.14

-14.03

-17.81

42.86

112.31

TG Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															46.09	-9.16	378.74	80.23	78.42

TG Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

TG Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(0.161	-	-1.308)	/	\| -1.308 \|
=	112.31 %

TG Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(-0.052	-	-0.241)	/	\| -0.241 \|
=	78.42 %

TG Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

TG Therapeutics (STU:NKB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (STU:NKB2) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

TGTX:USA NKB2:Germany

Address

3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560

Website

https://www.tgtherapeutics.com

TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics (STU:NKB2) Headlines

No Headlines